Becton Dickinson & Co. stock outperforms competitors despite losses on the day
Shares of Becton Dickinson & Co. (BDX) fell 1.61% to $155.54 on Monday, breaking a two-day winning streak. This occurred despite an overall positive trading session that saw the S&P 500 Index and the Dow Jones Industrial Average both rise. The article highlights how the stock performed relative to key market indexes.
Evercore ISI Adjusts Price Target on Becton, Dickinson and Company to $180 From $190
Evercore ISI has revised its price target for Becton, Dickinson and Company (NYSE:BDX) to $180, down from the previous $190. The adjustment reflects an updated outlook from the analyst firm. Becton, Dickinson and Company is a medical technology company specializing in medical and diagnostic equipment and materials.
Becton Dickinson stock holds the focus. Business context remains the anchor.
Becton Dickinson (BDX) stock is centered on its medical technology footprint and consistent hospital demand, with operations spanning diagnostics, medication delivery, and biosciences. The company's New York listing provides a crucial reference point for US healthcare spending and device demand. Without new company-specific catalysts, the stock's performance is currently driven by operating execution, margin discipline, and general medical spending trends across the sector.
Does Vizient’s CentroVena One Deal and Index Shuffle Change The Bull Case For Becton Dickinson (BDX)?
Becton Dickinson (BDX) recently received an Innovative Technology contract from Vizient for its CentroVena One Insertion System, signaling potential for improved safety and workflow in hospitals. This positive development reinforces BD's focus on high-value medtech solutions, offsetting recent news like the FDA's revocation of EUA for a rapid COVID-19 test and its re-indexing within the Russell indices. The article explores how this contract could impact BDX's investment narrative, emphasizing innovation-led growth opportunities despite existing challenges and providing a fair value estimate.
Does Vizient’s CentroVena One Deal and Index Shuffle Change The Bull Case For Becton Dickinson (BDX)?
Becton Dickinson (BDX) recently received an Innovative Technology contract from Vizient for its CentroVena One Insertion System, signaling an industry acknowledgment of its safety and workflow improvements. While the FDA revoked EUA for its BD Veritor rapid SARS-CoV-2 test, this does not significantly alter BD's investment narrative, which centers on its broad medtech portfolio and innovation offsetting margin pressures and regulatory risks. This contract reinforces BD's strategy towards high-value, differentiated solutions, providing an early proof point for innovation-led growth.
Earnings call transcript: Becton Dickinson Q2 2026 beats earnings expectations
Becton Dickinson (BDX) exceeded Q2 2026 earnings expectations with an adjusted EPS of $2.90 on revenues of $4.7 billion, leading to a 3.9% rise in pre-market trading and increased full-year EPS guidance. The company highlighted strong growth in sectors like biologic drug delivery and advanced patient monitoring, alongside strategic initiatives for operational excellence and capital allocation, including share repurchases and maintaining a disciplined M&A approach. CEO Tom Polen and CFO Vitor Roque discussed the continued execution of the "new BD" strategy and confident outlook despite anticipated headwinds in certain markets.
Becton Dickinson outlines its role in global healthcare. The company’s stock reflects long-term de
Becton Dickinson is a global medical technology company providing medical devices and diagnostic systems worldwide. Its stock performance is influenced by healthcare spending, regulatory developments, and demand for reliable medical equipment. The company's strategy includes organic growth, strategic acquisitions, and significant investment in R&D, focusing on improving patient safety and supporting healthcare professionals.
Rep. Thomas H. Kean, Jr. Acquires Amcor PLC (NYSE:AMCR) Stock
Representative Thomas H. Kean, Jr. recently purchased between $1,001 and $15,000 worth of Amcor PLC (NYSE:AMCR) stock on May 14th through his KEAN FAMILY PARTNERSHIP account. Amcor reported strong quarterly earnings, meeting EPS estimates and exceeding revenue expectations. The company offers an attractive 5.8% dividend yield and has an average analyst rating of "Moderate Buy" with a consensus target price of $48.00.
CLPT - ClearPoint Neuro Inc Volatility & Greeks
This article provides a detailed financial overview of ClearPoint Neuro Inc (CLPT), including its stock performance, key financial metrics, and volatility indicators. It lists various financial ratios, employee and ownership data, and price performance over different periods. The data presented covers the company's valuation, profitability, growth rates, and short interest.
BWAY - Brainsway Ltd ADR Options
This article provides a detailed financial overview of Brainsway Ltd ADR (BWAY), including its recent stock performance, key financial metrics, and valuation ratios. It lists various indicators such as market capitalization, income, sales, P/E ratio, EPS growth, insider and institutional ownership, and profitability margins. The data suggests an in-depth look into the company's financial health and market position.
BLFS - Biolife Solutions Inc Options
This article provides comprehensive financial data and stock performance metrics for Biolife Solutions Inc. (BLFS), including its last close price, market capitalization, income, sales, key financial ratios, EPS, and insider/institutional ownership details. It also features various performance indicators over different timeframes and analyst recommendations.
Beyond the Lawsuit: Embecta's Pen Needle Business Faces Structural Decline
Embecta's Q2 2026 earnings report revealed a significant decline in its pen needle business, triggering a class-action lawsuit alleging concealed competitive threats. Despite a growing overall market for pen needles, the company is struggling with commoditization, low-cost competitors, and the rise of alternative insulin delivery methods. The article concludes that Embecta appears to be a value trap due to its debt, negative book value, and ongoing credibility issues, advising extreme caution for investors.
Becton Dickinson stock holds its setup. Focus shifts to business fundamentals.
Becton Dickinson (BDX) stock continues to hold its ground, with investors focusing on the company's fundamental business operations rather than new catalysts. The medical technology giant, listed on the New York market, benefits from its broad portfolio of essential hospital and lab products. The article emphasizes that BD's consistent operational execution and market position are key drivers for its stock performance.
Becton Dickinson stock holds its ground. Focus turns to the medical device maker's portfolio.
Becton Dickinson (BD), a New York Stock Exchange-listed medical technology company, maintains its market position due to its broad portfolio spanning diagnostics, medication management, and biosciences. The article highlights that BD's stock performance is driven by its scale, product breadth, and healthcare exposure, with analysts focusing on demand stability and operational execution rather than new headline catalysts. BD serves hospitals and laboratories globally, generating recurring revenue from instruments, consumables, and workflow tools.
TFX - Teleflex Incorporated Earnings
This article provides a comprehensive snapshot of Teleflex Incorporated (TFX) financial data and key performance indicators. It covers market valuation, income statement figures, dividend information, analyst estimates, insider and institutional ownership, and various stock performance metrics. The data reflects the company's financial health and market activity up to the last close on July 2nd.
COO - Cooper Companies Inc Options
This article provides a detailed financial overview of Cooper Companies Inc (COO), including its last close price, various financial ratios, performance metrics, and insider/institutional ownership data. It lists key financial figures such as market cap, income, sales, P/E ratio, and EPS, alongside stock performance over different periods and analyst recommendations.
INSP - Inspire Medical Systems Inc Options
This article provides a detailed financial overview of Inspire Medical Systems Inc (INSP), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators, analyst recommendations, and insider/institutional ownership details. The data suggests a company with significant sales growth in the past but facing challenges in EPS projections and long-term stock performance.
Becton Dickinson & Co. stock outperforms competitors on strong trading day
Shares of Becton Dickinson & Co. (BDX) rose 3.39% to $158.08 on Thursday, marking its second consecutive day of gains. This performance outpaced the broader market, as the S&P 500 Index remained largely unchanged and the Dow Jones Industrial Average saw a modest increase. The article highlights the stock's strong trading session relative to its competitors.
RMD - Resmed Inc Latest SEC Filings
This article provides an overview of ResMed Inc. (RMD)'s latest financial data and stock performance as of July 2, 2026. It includes key metrics such as market capitalization, income, sales, dividend information, and various financial ratios. The report also details insider and institutional ownership, profitability margins, and historical stock performance.
Axogen (AXGN) Left Russell Indices, Is The Upside Already Priced In?
Axogen (AXGN) has been removed from several Russell indices, causing a 4.7% share price decline, although it still boasts significant year-to-date and 1-year returns. Conflicting valuation narratives exist, with one model suggesting it's 13.3% undervalued at $50.78 due to strong growth in peripheral nerve repair, while another DCF model calculates a fair value of $34.47, indicating the current price of $44.02 is expensive. The article advises investors to assess the numbers themselves.
What Tandem Diabetes Care (TNDM)'s CGM Expansion and New Tubeless Rival Mean For Shareholders
Tandem Diabetes Care recently expanded its t:slim X2 insulin pump's compatibility with Abbott's FreeStyle Libre 3 Plus CGM in Europe, while facing new competition from Modular Medical's Pivot tubeless insulin patch pump. This dual development highlights both the growth of Tandem's ecosystem and increasing competitive pressures in the insulin delivery market. The article suggests this situation could lead to a mix of international expansion opportunities and risks from new tubeless rivals for Tandem shareholders.
Becton Dickinson holds steady as investors await a fresh catalyst
Becton Dickinson (BDX) is trading with a muted tone as investors await new catalysts, focusing instead on its core operating profile and market context. The healthcare company, known for medical devices and diagnostics, relies on recurring demand from hospitals, linking its stock performance to procedure volumes and healthcare spending. Without new market-moving disclosures, investors are looking to upcoming earnings, margin trends, and management commentary for direction.
MMSI - Merit Medical Systems Inc Latest SEC Filings
This article provides the latest SEC filings for Merit Medical Systems Inc. (MMSI), along with comprehensive financial data, performance metrics, and key statistics. It includes information on the company's valuation, profitability, growth rates, and institutional ownership, offering a snapshot of its financial health and market position.
List of 36 Acquisitions by Becton Dickinson (Jul 2026)
Becton Dickinson has made 36 acquisitions across 22 sectors and 9 countries, with the United States, United Kingdom, and Canada being the most active regions. The company's most recent acquisition was MedKeeper in July 2022, which provides software for hospitals and retail pharmacies. Becton Dickinson was most active in 2021 with seven acquisitions, and the average number of acquisitions per year from 2020 to 2025 is two.
Becton Dickinson & Co. stock underperforms Wednesday when compared to competitors despite daily gains
Becton Dickinson & Co. (BDX) stock rose 1.04% to $152.90 on Wednesday, outperforming the S&P 500 and Dow Jones Industrial Average, which both saw declines. Despite the daily gains, the stock underperformed when compared to its competitors. This rise ended a two-day losing streak for BDX.
LMAT - Lemaitre Vascular Inc Latest SEC Filings
This article provides a detailed financial overview and recent SEC filing information for Lemaitre Vascular Inc (LMAT). It includes current stock performance metrics, key financial ratios, insider and institutional ownership data, and various performance indicators across different timeframes. The company's stock closed at $98.74, up 2.90% on July 1st.
Becton Dickinson and : BD Appoints Matthew Sassone as Worldwide President of Pharmacy Automation
Becton, Dickinson and Company (BD) has appointed Matthew Sassone as the worldwide president of BD Pharmacy Automation, a global business unit within its Medication Management Solutions. Sassone will be responsible for leading the global strategy, performance, and growth of the Pharmacy Automation business, focusing on innovation and expanding market presence. He brings over 20 years of experience in medical technology and previously served as CEO of Tristel plc.
BD Appoints Matthew Sassone as Worldwide President of Pharmacy Automation
BD (Becton, Dickinson and Company) announced the appointment of Matthew Sassone as the worldwide president of BD Pharmacy Automation, effective immediately. In this role, Sassone will be responsible for leading the global strategy, performance, and growth of the Pharmacy Automation business within BD's Connected Care segment. He brings over 20 years of experience in medical technology and will focus on advancing innovation and expanding market presence in healthcare settings.
BD (BDX) Receives Vizient Innovative Technology Contract for CentroVena One Insertion System
Becton, Dickinson & Company (NYSE: BDX) has secured an Innovative Technology contract from Vizient for its CentroVena One Insertion System. This system streamlines central line placement by integrating essential components, reducing procedural steps and time, and mitigating risks. The contract aims to enhance accessibility to Vizient's healthcare network, improving consistency, efficiency, and quality of care.
BD (BDX) Receives Vizient Innovative Technology Contract for CentroVena One Insertion System
BD (Becton, Dickinson & Company) has been awarded an Innovative Technology contract by Vizient for its CentroVena One Insertion System. This system streamlines central line placement by integrating essential components into a single device, reducing procedural steps and time, and mitigating risks. The contract makes this technology more accessible to healthcare providers, aiming to improve procedural consistency, operational efficiency, and quality of care.
Guardian Pharmacy (NYSE:GRDN) Joins Russell 2000 Defensive Indices
Guardian Pharmacy Services (NYSE:GRDN) has been added to the Russell 2000 Defensive Indices, a move stemming from the annual Russell index reconstitution. The company operates in the healthcare sector, specializing in long-term care pharmacy solutions including medication management, clinical consultation, and pharmaceutical services. This inclusion highlights its expanding operations and role within the healthcare industry.
Becton Dickinson (NYSE:BDX) Advances in NYSE Composite After Vizient Deal
Becton Dickinson (NYSE:BDX) has seen advancements in the NYSE Composite Index due to its medical technology initiatives, expanded product developments, and strong presence in the healthcare sector. The company's diversified global operations contribute to its position within the index. The article highlights Becton Dickinson's focus on healthcare innovation and its listing on the New York Stock Exchange.
Becton Dickinson (BDX) Wins Vizient Contract As Fair Value Stays In Focus
Becton Dickinson (BDX) is gaining attention due to a new Vizient contract for its BD CentroVena One Insertion System, an FDA transition request for COVID-19 testing, and upcoming Russell index reclassification. Despite a year-to-date share price drop of 22.37%, the stock is considered potentially undervalued by 16.5% with a fair value estimate of $181.23 per share. The company's impending transformation into a pure-play medical technology leader, focusing on consumables and aggressive share buybacks, is expected to enhance cash flow predictability and EPS growth.
Resmed sets Aug. 6 webcast for fiscal Q4 results
Resmed (NYSE: RMD) announced it will release its fourth quarter fiscal year 2026 financial and operational results on Thursday, August 6, 2026, after the NYSE closes. Management will host an earnings webcast at 1:30 p.m. PT / 4:30 p.m. ET, accessible via its investor relations website, with replay options available. The announcement also detailed phone replay access until August 20, 2026.
Sinha named executive vice president and chief people officer at BD
Manish Sinha has been appointed executive vice president and chief people officer at BD (Becton Dickinson), where he will lead the company's human resources function. With over 15 years at BD, Sinha brings extensive experience in talent, culture, and organizational design, having previously served as senior vice president of human resources and organizational effectiveness. In his new role, he is responsible for driving BD’s long-term growth, innovation agenda, and operational excellence.
Becton Dickinson & Co. stock underperforms Tuesday when compared to competitors
Becton Dickinson & Co. (BDX) stock fell 2.49% on Tuesday, closing at $151.33. This underperformance occurred despite a positive trading session for the broader market, with the S&P 500 Index rising 0.79% and the Dow Jones Industrial Average gaining 0.26%. The decline marked the stock's second consecutive day of losses.
Evotec launches J.TRAIN for rapid, cost-effective biologics manufacturing in partner facilities.
Evotec SE has launched J.TRAIN, a new service designed to allow biopharma companies to implement Evotec's continuous manufacturing technology within their own facilities. This solution offers a fast, flexible, and cost-effective way to produce biologics, capable of yielding over 500 kilograms of drug substance in a compact footprint and short deployment time. The innovation aims to enhance productivity and reduce costs, evidenced by a recent agreement with Sandoz.
Becton, Dickinson and Company(NYSE: BDX) added to Russell Midcap Value Benchmark
Becton, Dickinson and Company (NYSE: BDX) has been added to the Russell Midcap Value Benchmark. This news comes amidst other recent updates for the company, including securing a Vizient Innovative Technology Contract for its Centrovena One Insertion System and several FDA Class I recalls for various BD Spinal Tray products.
Is Vizient’s Nod to BD CentroVena One Quietly Reframing Becton Dickinson’s (BDX) Competitive Moat?
Becton Dickinson's BD CentroVena One Insertion System has received an Innovative Technology contract from Vizient, an endorsement that could significantly influence purchasing decisions within the healthcare network. This recognition highlights the system’s potential for simplifying central line placement and enhancing safety, reinforcing BD's innovation narrative despite existing risks like tariffs and regulatory pressures. The contract is expected to strengthen the product's adoption in acute care and support BD's goal of maintaining margins through new product launches.
Is Vizient’s Nod to BD CentroVena One Quietly Reframing Becton Dickinson’s (BDX) Competitive Moat?
Becton, Dickinson and Company (BDX) recently received an Innovative Technology contract from Vizient for its BD CentroVena One Insertion System, which could enhance its market penetration. This endorsement supports BD's innovation narrative, reinforcing that new products can help maintain margins despite challenges like tariffs and pricing pressures. While positive for near-term product adoption, the contract doesn't mitigate broader risks such as geopolitical trade issues or the planned Biosciences and Diagnostics separation.
Is Vizient’s Nod to BD CentroVena One Quietly Reframing Becton Dickinson’s (BDX) Competitive Moat?
Becton, Dickinson and Company's BD CentroVena One Insertion System has received an Innovative Technology contract from Vizient, a recognition that could simplify central line placement and enhance safety. This endorsement is expected to modestly strengthen near-term product adoption in acute care for Becton Dickinson, although it doesn't alter central risks like tariff headwinds or China procurement pressure. While the Vizient contract supports BD's innovation narrative, investors are advised to consider broader market dynamics and the company's financial forecasts.
Baxter International focuses on long-term portfolio shift, shares in S&P 500 healthcare spotlight
Baxter International is undergoing a multi-year effort to refine its medical product portfolio, with investors closely monitoring its spin-off strategy and margin goals. The company, which is a global supplier of medical products, has been highlighting cost-saving initiatives and portfolio streamlining to expand operating margins, even as it navigates one-time costs related to the separation of its kidney care business. Analysts view the stock primarily based on the execution of its separation plan and debt reduction, with a consensus in the hold-to-buy range.
Bernstein SocGen resumes Waters stock coverage with outperform rating By Investing.com
Bernstein SocGen has resumed coverage on Waters Corp. with an outperform rating and a $435 price target, noting the stock's strong first quarter 2026 report and raised guidance after previous pressures from tariff impacts and a merger announcement in 2025. Despite being considered overvalued by InvestingPro, Waters has seen renewed investor confidence, trading close to its historical median and showing significant gains in the past week. Recent company news includes new product launches for battery testing and biopharmaceutical impurity separation, along with a strategic partnership with IMU Biosciences, while Piper Sandler also initiated coverage with a Neutral rating.
Michael Feld sells $11,460 of Becton Dickinson stock By Investing.com
Michael Feld, EVP and Chief Revenue Officer at Becton Dickinson & Co. (NYSE:BDX), sold 75 shares of company stock for $11,460 on June 26, 2026, under a Rule 10b5-1 trading plan. Despite the insider sale, the stock has risen, and InvestingPro analysis suggests BDX is undervalued with a "GREAT" financial health score and a 2.69% dividend yield. The company has also announced new products and strategic initiatives, including the Elyra Thulium Fiber Laser System and an Innovative Technology contract for its CentroVena One Insertion System.
Insider Sell: Michael Feld Sells Shares of Becton Dickinson & Co (BDX)
Michael Feld, Executive Vice President and Chief Revenue Officer at Becton Dickinson & Co (BDX), sold 75 shares of the company on June 26, 2026. This transaction brings his total holdings to 21,009 shares. Over the past year, Feld has sold 770 shares and made no purchases, contributing to a trend of 1 insider buy against 21 insider sells for BDX within the same period.
Michael Feld sells $11,460 of Becton Dickinson stock
Michael Feld, EVP and Chief Revenue Officer at Becton Dickinson & Co. (NYSE:BDX), sold 75 shares of company stock for $11,460 on June 26, 2026, under a Rule 10b5-1 trading plan. Despite the sale, the stock price has since increased, and InvestingPro analysis suggests BDX is undervalued with strong financial health and a history of consecutive dividend increases. The company has also recently launched new medical devices and issued notes, highlighting strategic growth.
Enterprise value to EBIT forward of Becton, Dickinson and Company – NYSE:BDX
This article displays financial data for Becton, Dickinson and Company (NYSE: BDX), specifically its enterprise value to EBIT forward. It presents this data within the context of TradingView's platform, indicating various available financial metrics and tools for analysis.
Becton Dickinson & Co. stock outperforms competitors on strong trading day
Becton Dickinson & Co. (BDX) stock advanced 3.00% to $155.92, outperforming its competitors on a day where the S&P 500 and Dow Jones Industrial Average experienced slight declines. This marks the stock's fourth consecutive day of gains. The article attributes the content to MarketWatch Automation, supported by Dow Jones and FactSet.
SNT Biotech Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
SNT Biotech has partnered with Waters Corporation to expand access to at-home HPV cervical cancer screenings using the FDA-cleared Onclarity™ HPV Self-Collection Kit. This initiative aims to address the low screening rates among underserved populations and improve early detection, as cervical cancer is largely preventable but still claims many lives annually. The comprehensive solution combines advanced diagnostics with a patient-centric engagement platform to ensure high completion and return rates for screening kits.
Bernstein SocGen resumes Waters stock coverage with outperform rating
Bernstein SocGen Group has initiated coverage on Waters Corp. (NYSE:WAT) with an "outperform" rating and a price target of $435.00, citing the company's strong replacement cycle and recent segment recovery. Despite the stock trading above InvestingPro's Fair Value estimate, making it appear overvalued in the analytical instruments sector, recent positive developments like a strong Q1 2026 report and raised guidance have supported its share price. Waters has also been active with new product launches and strategic partnerships, including a collaboration with IMU Biosciences, further enhancing its market position.
